Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 783, Issue -, Pages 23-32Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2016.04.052
Keywords
Alzheimer disease; Amyloid beta protein; GLP-1; GSK-3 beta; Tau protein
Categories
Funding
- Science and Technology Key Funding of Fujian Province of China [2013Y0041]
- Youth Funding of Fujian Province Health Department [2011-1-10]
- China International Medical Foundation (CIMF)-Novo Nordisk China Diabetes Young Scientific Talent Research Funding [2013-1]
- Natural Science Foundation of Fujian Province of China [2014J01335]
Ask authors/readers for more resources
Type 2 diabetes mellitus is a risk factor for Alzheimer's disease (AD). The glucagon-like peptide-1 analog liraglutide, a novel long-lasting incretin hormone, has been used to treat type 2 diabetes mellitus. In addition, liraglutide has been shown to be neurotrophic and neuroprotective. Here, we investigated the effects of liraglutide on amyloid beta protein (A beta)-induced AD in mice and explored its mechanism of action. The results showed that subcutaneous administration of liraglutide (25nmol/day), once daily for 8 weeks, prevented memory impairments in the Y Maze and Morris Water Maze following A beta(1-42) intracerebroventricular injection, and alleviated the ultra-structural changes of pyramidal neurons and chemical synapses in the hippocampal CA1 region. Furthermore, liraglutide reduced A beta(1-42)-induced tau phosphorylation via the protein kinase B and glycogen synthase kinase-3 beta pathways. Thus liraglutide may alleviate cognitive impairment in AD by at least decreasing the phosphorylation of tau. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available